Abbott Laboratories
Abbott Laboratories reported a robust 7.5% organic sales growth in Q3 2025, primarily driven by a strong performance in medical devices and established pharmaceuticals, despite a decline in COVID test sales.
Key takeaways
- Earnings per share rose to $1.30, reflecting high single-digit growth year-over-year, excluding COVID test impacts.
- New product launches contributed nearly $5 billion in sales this quarter, adding over 100 basis points to organic sales growth.
- Medical Devices segment grew by 12.5%, led by solid performances in diabetes care and electrophysiology.
- Established Pharmaceuticals experienced high single-digit growth, driven by strong contributions from core markets and therapeutic areas.
- Strategic investments in nutrition products are set to leverage favorable consumer trends, evidenced by new launches in the adult nutrition segment.